Fat LossMedium Risk

Cagrilintide

Also known as: AM833

Half-life:: ~7 days

Administration Routes

subcutaneous injection

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination

A once-weekly long-acting amylin analogue in late-stage development. Showing impressive weight loss (~15%) in trials, especially when combined with semaglutide (CagriSema).

Primary Research Areas

sustained appetite suppression
weight loss
metabolic regulation

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyInvestigational

Amylin analog by Novo Nordisk. Phase 3 as CagriSema (+ semaglutide, NCT05669755) for obesity. Not yet approved. NDA submission anticipated 2026-2027 if trials succeed.

View FDA source →

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Cagrilintide

No active associated providers listed yet.